BLOOD PRESSURE AND PLASMA FGF-23 CONCENTRATION CHANGES AFTER CINACALCET TREATMENT IN HEMODIALYZED PATIENTS WITH CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYROIDISM

被引：0
|
作者：
Adamczak, M. [1 ]
Kuczera, P. [1 ]
Wiecek, A. [1 ]
机构：
[1] Dept Nephrol Transplantol & Internal Med, Katowice, Poland
来源：
JOURNAL OF HYPERTENSION | 2015年 / 33卷
关键词：
D O I：
10.1097/01.hjh.0000468926.58110.3f
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
PP.39.14
引用
收藏
页码：E488 / E489
页数：2
相关论文
共 50 条
  • [21] FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment
    Seiler, Sarah
    Reichart, Birgit
    Roth, Daniel
    Seibert, Eric
    Fliser, Danilo
    Heine, Gunnar H.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (12) : 3983 - 3989
  • [22] Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease
    Quarles, LD
    KIDNEY INTERNATIONAL, 2005, 68 : S24 - S28
  • [23] New Insights into the Role of FGF-23 and Klotho in Cardiovascular Disease in Chronic Kidney Disease Patients
    Memmos, Evangelos
    Papagianni, Aikaterini
    CURRENT VASCULAR PHARMACOLOGY, 2021, 19 (01) : 55 - 62
  • [24] ASSOCIATIONS OF FGF-23 AND KLOTHO SERUMLEVELS WITH CARDIOVASCULAR RISK IN CHRONIC KIDNEY DISEASE PATIENTS
    Dudareva, Anna
    Milovanova, Ludmila
    Brovko, Mihail
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 1432 - 1432
  • [25] Experience with Cinacalcet for Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Stage III and IV
    Forslund, Terje
    Koistinen, Arvo
    Miettinen, Marja
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 801 - 808
  • [26] FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease
    Yilmaz, Mahmut I.
    Sonmez, Alper
    Saglam, Mutlu
    Yaman, Halil
    Kilic, Selim
    Demirkaya, Erkan
    Eyileten, Tayfun
    Caglar, Kayser
    Oguz, Yusuf
    Vural, Abdulgaffar
    Yenicesu, Mujdat
    Zoccali, Carmine
    KIDNEY INTERNATIONAL, 2010, 78 (07) : 679 - 685
  • [27] FGF-23 AS AN EARLY MARKER OF BONE AND MINERAL DISTURBANCES IN CHRONIC KIDNEY DISEASE PATIENTS
    Martynyuk, L.
    Chaykovska, M.
    Butvyn, S.
    Shershun, O.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S330 - S330
  • [28] Sclerostin and FGF-23 Protein Expression in Bone of Patients with Chronic Kidney Disease.
    Lima, Florence
    David, Valentin
    Mawad, Hanna
    Malluche, Hartmut
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 : S54 - S54
  • [29] FGF-23 AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: AN INDIAN PERSPECTIVE
    Mogili, Harikrishna Reddy
    Venkata, Anilkumar C.
    Ram, R.
    Vishnubotla, Sivakumar
    Koratala, Abhilash
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2018, 71 (04) : 567 - 567
  • [30] SERUM TOTAL AND FREE TESTOSTERONE CONCENTRATION IN MALE HEMODIALYSED PATIENTS WITH CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYROIDISM TREATED WITH CINACALCET
    Kuczera, Piotr
    Adamczak, Marcin
    Wiecek, Andrzej
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
12345